Literature DB >> 2644963

Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites.

J W Sear1, C W Hand, R A Moore, H J McQuay.   

Abstract

The influence of renal failure on the disposition of morphine and its metabolites was studied in nine patients with end-stage renal failure undergoing transplantation, and compared with five healthy anaesthetized patients. All patients received morphine sulphate pentahydrate 10 mg i.v. over 30 s, as part of a balanced anaesthetic technique. Venous blood samples were collected for up to 24 h, and plasma concentrations of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) assayed by a differential radioimmunoassay method. There were no differences between the two groups for morphine elimination half-life (renal failure: 290 min; anaesthetized controls: 286 min), or clearance (renal failure: 533 ml min-1; controls 741 ml min-1). However, the volume of distribution at steady state was greater in the control group (241 litre v. 141 litre; P = 0.002). The peak concentrations of M3G and M6G were greater in the renal transplant patients (P = 0.001 and P = 0.01, respectively), as were the AUC (0-24 h) (P = 0.002 and P = 0.002). M6G has been shown to possess analgesic properties in both man and experimental animals, and therefore the increased AUC for M6G may contribute to the prolonged effect seen with morphine when given to patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644963     DOI: 10.1093/bja/62.1.28

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  19 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  [The role of morphine-6-glucuronide during longterm administration of morphine.].

Authors:  M Prokopek; A Ziegler
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

Review 5.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

6.  Volume of hydration in terminal cancer patients.

Authors:  E Bruera; M Belzile; S Watanabe; R L Fainsinger
Journal:  Support Care Cancer       Date:  1996-03       Impact factor: 3.603

Review 7.  Morphine for chronic neuropathic pain in adults.

Authors:  Tess E Cooper; Junqiao Chen; Philip J Wiffen; Sheena Derry; Daniel B Carr; Dominic Aldington; Peter Cole; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-05-22

Review 8.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

9.  Concerns about dehydration/starvation.

Authors:  J K Hall
Journal:  J Gen Intern Med       Date:  1994-02       Impact factor: 5.128

10.  Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.

Authors:  G M Peterson; C T Randall; J Paterson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.